Nagaraj Gowda

• My passion is pharmaceutical drug development My broad educational and work history in research, drug discovery and development from early-stage through different regulatory submissions, allows me to establish strong, collaborative relationships with company staff and corporate/academic alliances to reliably bring new therapies to the clinic. Core strengths:
• Leadership: My foundational approach is on motivation and facilitation to increase team productivity drawn from cross functional background belonging to multicultural and multinational makeup. I use active listening and multi-criterial decision making, all with an awareness of company culture. My focus is on achieving deliverables that meet company goals though innovation, team management and efficient resource utilization. Fostered a biotech culture by leading from front and risk-taking ability to discover new medicines.
• Innovation: Proven innovator in research and drug development. I have an industrial strength patent portfolio and a strong scientific publication record. I maintain a keen awareness of the company’s projects and objectives as well as the company’s province in medicine development.
• Strategy Development: Developing robust drug discovery and development strategy keeping in mind competitive intelligence and advances in the field. I seek and foster cross collaboration across the company, with project leads, and with academic/consultant partners to meet objectives. Such action is impactful when challenges occur but I also revel in the learning process it affords.
• Regulatory: Hands-on experience in IND regulatory submissions and interactions (pre-IND, Type B meetings) with FDA, DCGI and EU regulatory agencies. Successfully completed FDA audit for one of the clinical candidate with no observations.
• Therapeutic areas and platforms: Oncology and Immunology are major areas. Broad platform experience with small molecule drugs (inhibitor, degrader,) multi-specific antibodies and peptides.
• Bench Expertise: Immunology, Cell Biology, Biochemistry, Translation sciences and Biophysics.

Persistent leader eager to lead and grow organizations. Skilled in strategic planning, problem-solving, and communication with good understanding of business principles, project management and team leadership. Collaborative with relentless work ethic.

• American Association of Immunologists
• American Association for Cancer Research
• Society for Immunotherapy of Cancer (SITC)
• European Society for Medical Oncology Extra academic experiences

• · Delivered eleven clinical candidates and 1 IND ready candidate for Oncology and Immunology along with drug discovery team, including small molecule/peptide mimetic drug discovery projects (CA170 (PD-L1/VISTA peptidomimetic inhibitor) in Phase –III trial for non-squamous NSCLC, Emavusertib for R/R B-cell lymphomas and myeloid malignancies, anti-CD47 small molecule for R/R MM and TIGIT/PD-L1, HPK1 and Cbl-bInhibitors for solid malignancies. Multi-specific antibodies (anti-CD47 and anti-CD38 bi specific, anti-CD3/anti-CD38/anti-BCMA tri specific) for R/R MM.